Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Revvity, Inc. Common Stock (NY:RVTY)

91.66 -0.11 (-0.12%)
Official Closing Price Updated: 4:10 PM EDT, Oct 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Revvity, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Maryland Rep. April McClain Delaney Sold Over $54K Worth of A.O. Smith Stock: Here's What You Should Know
 
Via Benzinga
Revvity Expands Alliance with Genomics England to Drive Research into Newborn Genomic Sequencing in England
From Revvity
Via Business Wire
Stay informed with the top movers within the S&P500 index on Wednesday.
Stay updated with the movements of the S&P500 index one hour before the close of the markets on Wednesday. Discover which stocks are leading as top gainers and losers in today's session. 
Via Chartmill
What Does the Market Think About Revvity?
 
Via Benzinga
(RVTY) - Analyzing Revvity's Short Interest
 
Via Benzinga
Explore the top gainers and losers within the S&P500 index in today's session.
Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top S&P500 gainers and losers in today's session. 
Via Chartmill
Which S&P500 stocks are gapping on Wednesday?
Stay updated with the S&P500 gap up and gap down stocks on Wednesday. Get a glimpse of the market's movement during today's session. 
Via Chartmill
Revvity’s EUROIMMUN Receives CE Mark for Novel Measles Antibody Detection Assay
From Revvity
Via Business Wire
Forecasting The Future: 7 Analyst Projections For Revvity
 
Via Benzinga
These Analysts Revise Their Forecasts On Revvity Following Q3 Results
 
Via Benzinga
Winners And Losers Of Q4: Revvity (NYSE:RVTY) Vs The Rest Of The Research Tools & Consumables Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Revvity (NYSE:RVTY) and the best and worst... 
Via StockStory
Topics Economy
3 Reasons to Sell RVTY and 1 Stock to Buy Instead
Over the past six months, Revvity’s shares (currently trading at $111) have posted a disappointing 8.5% loss, well below the S&P 500’s 5.1% gain. This was partly due to its softer quarterly results and... 
Via StockStory
Topics Stocks
Revvity Wins Permanent Injunction Enforcing Agreements with Cloud Software Group
From Revvity
Via Business Wire
Revvity to Present at Upcoming Investor Conferences
From Revvity
Via Business Wire
Uncover the latest developments among S&P500 stocks in today's session.
Curious about the top performers within the S&P500 index in the middle of the day on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview. 
Via Chartmill
Revvity (NYSE:RVTY) Reports Q4 In Line With Expectations
Life sciences company Revvity (NYSE:RVTY) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 4.8% year on year to $729.4 million. On the other hand, the company’s full-year revenue... 
Via StockStory
Friday's pre-market session: top gainers and losers in the S&P500 index
Get insights into the top gainers and losers in the S&P500 index of Friday's pre-market session. 
Via Chartmill
Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2024
From Revvity
Via Business Wire
Earnings Scheduled For January 31, 2025
 
Via Benzinga
Revvity Board Declares Quarterly Dividend
From Revvity
Via Business Wire
Revvity and Element Biosciences Collaborate to Advance Sequencing-based IVD Neonatal Testing
From Revvity
Via Business Wire
Revvity to Hold Earnings Call on Friday, January 31, 2025; Provides Update on Financial Performance
From Revvity
Via Business Wire
Revvity Announces FDA Clearance for First Automated Free Testosterone Test
From Revvity
Via Business Wire
Revvity to Present at J.P. Morgan Healthcare Conference
From Revvity
Via Business Wire
Despite Higher Valuations, Some Life Sciences Tools Stocks Create Good Opportunities: Analyst
BofA upgrades Danaher and Revvity, predicting a mixed but improving outlook for life sciences tools in fiscal year 2025 amid ongoing market challenges. 
Via Benzinga
Revvity Broadens Relationship with Genomics England to Advance Genomics in the UK
From Revvity
Via Business Wire
Scale Biosciences and Revvity’s BioLegend Launch First-of-its-Kind Solution for High Parameter Protein Profiling of Single Cells
From Scale Biosciences
Via Business Wire
Revvity to Present at 7th Annual Evercore ISI HealthCONx Conference
From Revvity
Via Business Wire
Revvity to Host Investor Day and Updates Organizational Structure to Reflect Recent Transformation
From Revvity
Via Business Wire
Revvity Announces Financial Results for the Third Quarter of 2024
From Revvity
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.